Sanofi, Exscientia link to develop bispecific small molecule drugs

Under the alliance, Exscientia will use its platform to seek out and validate combinations of drug targets that could work synergistically and be amenable to its bispecific-small-molecule design strategy.

Spotlight

Other News

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More

Dom Nicastro | April 03, 2020

Read More